Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
Wei-Ying Diao,Cheng-Long Ding,Bo-Yang Yuan,Zan Li,Na Sun,Jia-Bin Huang
DOI: https://doi.org/10.2147/IJGM.S328908
IF: 2.145
2021-12-01
International Journal of General Medicine
Abstract:Wei-Ying Diao, 1, &ast Cheng-Long Ding, 1, &ast Bo-Yang Yuan, 2 Zan Li, 3 Na Sun, 4 Jia-Bin Huang 5 1 Department of Pathology, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People's Republic of China; 2 Department of Acupuncture and Moxibustion, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People's Republic of China; 3 Department of Analytical Chemistry Teaching and Research, Jiamusi University, Jiamusi City, Heilongjiang Province, 154002, People's Republic of China; 4 Graduate Department, Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People's Republic of China; 5 Department of Geratology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jia-Bin Huang Email Introduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients. Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to January 2018 were retrospectively analyzed. The clinicopathological information, CT signs, clinical efficacy and long-term prognosis were collected and compared. Results: A total of 249 NSCLC patients underwent HER2 gene testing, 21 of them (8.43%) complied with HER2 alterations [HER2 (+)], and there were significant differences in tumor stages among patients with different HER2 phenotypes ( P 0.05). The disease control rate of HER2 (+) patients was significantly lower than that of HER2 (-) patients, and the 12-month progression-free survival rate and survival rate of HER2 (+) patients were significantly higher than those of HER2 (-) patients ( P < 0.05). There was no significant difference in the incidence of ADR among HER2 patients with different phenotypes, but the incidence of ADR (adverse drug reaction) in HER2 (+) patients with Grade 3 or 4 was significantly higher than that in the control group ( P < 0.05). Discussion: The incidence of HER2 gene mutations in NSCLC patients is relatively low, but it is far commoner in patients with stage IIIB∼IV, among which exon 20 mutations are the most prevalent. In CT signs, the lesion lobulated sign/spiculated sign, necrosis signs, and pleural depression signs are related to HER2 gene mutations. In addition, HER2 gene mutations play a crucial role in the clinical prognosis and treatment safety of patients. Keywords: non-small cell lung cancer, HER2 genotype, CT signs, afatinib As one of the most prevalent malignant tumors worldwide, lung cancer has become the top cause of cancer-related death in the urban population of China. Non-small cell lung cancer (NSCLC) includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, in which cancer cells grow and divide more slowly, and spread and metastasize are less drastic. 1,2 NSCLC accounts for about 80% of overall lung cancers, and approximately 75% of patients have progressed in the advanced stage when diagnosed, with somber 5-year survival rate. 3 At present, the treatment of NSCLC mainly includes surgery, radiotherapy, chemotherapy, immunotherapy, etc. A large number of studies have shown that the occurrence and development of lung cancer are consequent to the unbalanced regulation of multiple gene expression, which is closely related to the stability of genes in organisms. 4,5 Human Epithelial Factor Receptor-2 (HER2) is a member of the epithelial factor receptor family. Studies demonstrated that HER2 overexpression is an enhancer of EGFR signaling, and it plays a role in signal transduction in cancer development and progress when HER2 is dysfunctional. 6 Afatinib and trezizumab have been recommended as targeted therapies for patients with HER2 mutation -Abstract Truncated-
medicine, general & internal